Novo Nordisk’s Buyback Momentum Meets Hemophilia Data Dump Ahead of Half-Year Checkpoint

Novo Nordisk has clawed back nearly 40% from its March trough, but the stock remains 27% lower than a year ago and still more than 31% below the July 2025 peak of €61.20. The recent acceleration — an 8.4% weekly gain to close Friday at €42.19 — has been fuelled by a relentless share-buyback programme and growing anticipation around a string of clinical catalysts. Yet the relative strength index now sits at 71.3, flashing an overbought signal that suggests the rally’s pace may be getting ahead of itself.

The buyback campaign is anything but modest. Since 4 February, Novo Nordisk has repurchased nearly 21 million B-shares at an average price of DKK?266.09, spending approximately DKK?5.58?billion — well over a third of the full-year target of DKK?15?billion. A separate tranche, launched in May, authorises further purchases of up to DKK?11.2?billion through 1 February 2027. Together, the company now holds 38.1?million treasury shares, representing about 0.9% of total share capital. Management’s decision to deploy such firepower signals a clear conviction that the stock is undervalued.

That conviction will be tested next week. From 11 to 15 July, Novo Nordisk is presenting fresh clinical data at the ISTH congress in Paris, with the experimental haemophilia A therapy Denecimig (Mim8) taking centre stage. The Phase?3 FRONTIER4 study is examining dosing intervals of once monthly, every two weeks, or weekly in adults, adolescents and children. Also for the first time, data from the Explorer10 study on Concizumab in children up to age 11 with haemophilia A or B with inhibitors will be unveiled. The timing is critical: Denecimig was submitted to the FDA for approval in September 2025, and regulators have yet to deliver their verdict. Investors will scrutinise these results for proof of clinical substance.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Outside the pipeline, a parallel signal of confidence arrived in early June. The Novo Nordisk Foundation launched the CardioMetabolic Bridge programme, a €60?million, six-year initiative run through the BioInnovation Institute in Copenhagen. It aims to accelerate academic research into obesity, diabetes and cardiovascular disease towards market-ready therapies, with an initial lab in London and subsequent outposts planned for Italy and Germany. Imperial College London is already among the partner institutions.

A smaller but notable pipeline bright spot emerged recently with Zenagamtid, a Phase?2 candidate for type?2 diabetes. At the highest dose, it reduced HbA1c by 1.71 percentage points over 36 weeks, and nearly 89% of patients hit the clinically relevant target of below 7%. Phase?3 studies are slated to start in the second half of 2026, with first data unlikely before 2028.

The next major milestone, however, is the half-year results due on 5 August. Analysts will focus on patient retention rates for the oral Wegovy formulation as a gauge of commercial traction. The company has guided for adjusted revenue growth of minus?5% to minus?13% in constant currencies for the full year, and the interim report will reveal whether that range is achievable or requires downward revision. Between the ISTH data dump, the buyback’s steady demand floor, and the half-year verdict, Novo Nordisk is navigating a dense corridor of events that will determine whether the recovery has real legs or is merely a technical rebound.

Ad

Novo Nordisk Stock: New Analysis - 28 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69647747 |